Showing results (21-30 of 689) with videos related to
Sort By:
Pageof 69
Current Opinion in Investigational Drugs (London, England : 2000)|May 12, 2004
The potential role of glucagon-like peptide 1 in diabetesJuris J Meier, Michael A NauckCurrent Diabetes Reports|August 11, 2006
Incretins and the development of type 2 diabetesJuris J Meier, Michael A NauckLancet (London, England)|November 14, 2006
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesDaniel J Drucker, Michael A NauckJournal of Diabetes Science and Technology|May 31, 2014
Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!Michael A Nauck, Juris J MeierDiabetologia|February 3, 2016
The insulinotropic effect of pulsatile compared with continuous intravenous delivery of GLP-1Mark P Plummer, Palash Kar, Caroline E Cousins, et al.Critical Care (London, England)|January 24, 2015
Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover studyPalash Kar, Caroline E Cousins, Christopher E Annink, et al.Metabolism: Clinical and Experimental|July 9, 2013
Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetesAmalia Gastaldelli, Michael A Nauck, Raffaella BalenaDrug News & Perspectives|December 12, 2003
Incretins and their analogues as new antidiabetic drugsMichael A Nauck, Juris J Meier, Werner CreutzfeldtThe Lancet. Diabetes & Endocrinology|June 28, 2021
Treatment of type 2 diabetes: challenges, hopes, and anticipated successesMichael A Nauck, Jakob Wefers, Juris J MeierPageof 69